Related Experiment Video
Updated: Jun 17, 2026

Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
Isoflavone intake and risk of lung cancer: a prospective cohort study in Japan
Taichi Shimazu1, Manami Inoue, Shizuka Sasazuki
1Research Center for Cancer Prevention and Screening, National Cancer Center Tokyo Japan. tshimazu@ncc.go.jp
Background:
Although case-control studies support the idea that soy foods or isoflavone intake is associated with a decreased risk of lung cancer, little evidence is available from prospective cohort studies. Moreover, no prospective study has addressed this association in men.
Objective:
We investigated the association between isoflavone intake and lung cancer incidence.
Design:
We conducted a population-based prospective cohort study in 36,177 men and 40,484 women aged 45-74 y with no history of cancer at baseline in 1995-1999. Participants responded to a validated questionnaire, which included 138 food items. We used Cox proportional hazards regression analysis to estimate the hazard ratios (HRs) and 95% CIs of lung cancer incidence according to isoflavone intake, which was estimated by genistein content from soy foods.
Results:
During 11 y (671,864 person-years) of follow-up, we documented 481 male and 178 female lung cancer cases. In men we found an inverse association between isoflavone intake and risk of lung cancer in never smokers (n = 13,051; multivariate HR in the highest compared with the lowest quartile of isoflavone intake: 0.43; 95% CI: 0.21, 0.90; P for trend = 0.024) but not in current or past smokers. A similar, nonsignificant inverse association was seen in never-smoking women (n = 38,211; HR: 0.67; 95% CI: 0.41, 1.10; P for trend = 0.135). We also tested effect modification by smoking status (P for interaction = 0.085 in men and 0.055 in men and women combined).
Conclusion:
In a large-scale, population-based, prospective study in Japan, isoflavone intake was associated with a decreased risk of lung cancer in never smokers.
Related Concept Videos
Cancer Prevention
Some...
Cancer Prevention
Some...
Bioavailability Study Design: Healthy Subjects Versus Patients
Bias in Epidemiological Studies
Relative Risk
Bioavailability Study Design: Absolute Versus Relative Bioavailability
